Editor ’s Message—Issue Highlights, July–August 2016

Dear Colleagues: Welcome to the July–August 2016 issue of Innovations in Clinical Neuroscience. We start this issue with an interesting study by MacEwan et al titled, “Pharmaceutical Innovation in the Treatment of Schizophrenia and Mental Disorders Compared with Other Diseases.” Here, the authors assessed the level of private and public investment in research and development (R&D) of treatments for schizophrenia and other mental disorders and compared this to other diseases. They present their data on the economic burden and pharmaceutical innovation by disease area and compare the level of investment relative to burden across different diseases. Perhaps not surprisingly, the authors found the level of investment and pharmaceutical innovation in mental disorders to be comparatively low, especially relative to the burden of disease. The authors discuss potential reasons for this lack of investment and innovation. How this problem can be resolved requires further elucidation. Next, Scarff provides a brief review of brexpiprazole, a new treatment option for schizophrenia. Based on the published studies, he describes the drug’s mechanisms of action, efficacy, tolerability (including adverse effects), dosing, and contraindications. Following this, in a review article by Fard et al titled, “The Potential Role of T Helper Cell 22 and IL-22 in Immunopathogenesis of Multiple Sclerosis” the authors discuss the newly identified T helper cell 22 (Th22), a subset of CD4+ T...
Source: Innovations in Clinical Neuroscience - Category: Neuroscience Authors: Tags: Current Issue Drug Development Editor's Message: Issue Highlights Neurology Psychiatry Amir Kalali Innovations in Clinical Neuroscience Source Type: research